Redefining drug development with precision therapeutics
Redefining drug development with precision therapeutics
Dysruptx is a University of Glasgow born biotechnology company developing a class of precision-guided peptide therapeutic known as 'Dysruptors'. Dysruptors are engineered from the point of discovery to maximise on-target activity while minimising off-target toxicity; addressing a dominant driver of clinical-stage drug failure
Dysruptx is a University of Glasgow born biotechnology company developing a class of precision-guided peptide therapeutic known as 'Dysruptors'. Dysruptors are engineered from the point of discovery to maximise on-target activity while minimising off-target toxicity; addressing a dominant driver of clinical-stage drug failure
Dysruptx is a University of Glasgow born biotechnology company developing a class of precision-guided peptide therapeutic known as 'Dysruptors'. Dysruptors are engineered from the point of discovery to maximise on-target activity while minimising off-target toxicity; addressing a dominant driver of clinical-stage drug failure
01
Naturally precise by design
Naturally precise by design
Naturally precise by design
Naturally precise by design
Protein–protein interactions have evolved over millions of years to achieve remarkable specificity within complex biological systems.
Protein–protein interactions have evolved over millions of years to achieve remarkable specificity within complex biological systems.
02
Mapping the interface
Mapping the interface
Mapping the interface
Mapping the interface
Dysruptx starts with these naturally evolved interaction sites to identify highly relevant binding patterns from the outset.
Dysruptx starts with these naturally evolved interaction sites to identify highly relevant binding patterns from the outset.
03
Designing Dysruptors
Designing Dysruptors
Designing Dysruptors
Designing Dysruptors
From this interface knowledge, Dysruptx develops macrocyclic peptide Dysruptors engineered to mimic and disrupt disease-relevant interactions with precision.
From this interface knowledge, Dysruptx develops macrocyclic peptide Dysruptors engineered to mimic and disrupt disease-relevant interactions with precision.
04
Selectivity from the start
Selectivity from the start
Selectivity from the start
Selectivity from the start
By addressing off-target toxicity early in discovery, Dysruptx supports a more selective and potentially safer path for targeted therapeutic development.
By addressing off-target toxicity early in discovery, Dysruptx supports a more selective and potentially safer path for targeted therapeutic development.
We’re developing precision macrocyclic peptide therapeutics designed to treat human disease while reducing off-target toxicity from the earliest stages of discovery.
We’re developing precision macrocyclic peptide therapeutics designed to treat human disease while reducing off-target toxicity from the earliest stages of discovery.
We’re developing precision macrocyclic peptide therapeutics designed to treat human disease while reducing off-target toxicity from the earliest stages of discovery.
Selective binding
Protein targeting
Selective binding
Protein targeting
Vision
Advancing a more precise therapeutic paradigm
Advancing a more precise therapeutic paradigm
We are focused on enabling the development of targeted therapies with improved selectivity and safety profiles, supporting more reliable translation from discovery to clinic.
We are focused on enabling the development of targeted therapies with improved selectivity and safety profiles, supporting more reliable translation from discovery to clinic.
Approach
Precision-guided by design
Precision-guided by design
Dysruptx is developing a platform-driven approach to therapeutic design, focused on minimising off-target interactions early in the discovery process. Our work is centred on improving selectivity without compromising efficacy, a balance critical to advancing next-generation therapeutics.
Dysruptx is developing a platform-driven approach to therapeutic design, focused on minimising off-target interactions early in the discovery process. Our work is centred on improving selectivity without compromising efficacy, a balance critical to advancing next-generation therapeutics.
Selective binding
Protein targeting
Selective binding
Protein targeting
Designed for precision.
Built for impact.
Selective by design
Engineered to improve target specificity from the outset
Mechanism-driven
Grounded in protein–protein interaction biology to guide discovery
Mechanism-driven
Grounded in protein–protein interaction biology to guide discovery
Risk addressed early
Focused on reducing failure drivers at the discovery stage
Risk addressed early
Focused on reducing failure drivers at the discovery stage
Platform-driven
Structured to enable both internal development and partnerships
Platform-driven
Structured to enable both internal development and partnerships
Designed for precision.
Built for impact.
Selective by design
Engineered to improve target specificity from the outset
Mechanism-driven
Grounded in protein–protein interaction biology to guide discovery
Risk addressed early
Focused on reducing failure drivers at the discovery stage
Platform-driven
Structured to enable both internal development and partnerships
Designed for precision.
Built for impact.
Selective by design
Engineered to improve target specificity from the outset
Mechanism-driven
Grounded in protein–protein interaction biology to guide discovery
Risk addressed early
Focused on reducing failure drivers at the discovery stage
Platform-driven
Structured to enable both internal development and partnerships